AC-PHE-GLU-TRP-THR-PRO-GLY-TRP-TYR-GLN-L-AZETIDINE-2-CARBONYL-TYR-ALA-LEU-PRO-LEU-NH2
AC-PHE-GLU-TRP-THR-PRO-GLY-TRP-TYR-GLN-L-AZETIDINE-2-CARBONYL-TYR-ALA-LEU-PRO-LEU-NH2
AC-PHE-GLU-TRP-THR-PRO-GLY-TRP-TYR-GLN-L-AZETIDINE-2-CARBONYL-TYR-ALA-LEU-PRO-LEU-NH2 性质
熔点 | >179°C (dec.) |
---|---|
密度 | 1.353±0.06 g/cm3(Predicted) |
储存条件 | −20°C |
溶解度 | DMSO(微溶)、甲醇(微溶)、水(微溶) |
酸度系数(pKa) | 4.44±0.10(Predicted) |
形态 | 固体 |
颜色 | 白色至类白色 |
AC-PHE-GLU-TRP-THR-PRO-GLY-TRP-TYR-GLN-L-AZETIDINE-2-CARBONYL-TYR-ALA-LEU-PRO-LEU-NH2 用途与合成方法
IL1R1 8 mM (IC 50 ) |
AF12198 competes for binding of 125 I-IL-1α with an IC 50 of 8.0 nM, nearly equal to that of IL-1ra, IC 50 of 4.0 nM for the type I receptor.AF12198 (0-5 ng; 8 hours) inhibits IL-6 induction with an IC 50 of 15 μM whereas IL-1ra inhibits with an IC 50 of 2 nM in heparinized human primate blood. Meanwhile, With blood from cynomolgus monkeys, the IC 50 values are 17 μM for AF12198 and 30 nM for IL-1ra. Additionally, AF12198 or IL-1RA alone does not induce IL-6 in blood from either humans or cynomolgus monkeys.
AF12198 (intravenous infusion; 16 mg/kg; 30 min before LPS intravenous injection) significantly attenuates the increase in lung MPO activity induced by LPS in acute lung inflammation and it reduces the lung microvascular leakage from rats inflamed with LPS at the 4 h (32.6%), 12 h (50.1%) and 24 h (65.3%) after LPS.
Animal Model: | Male Wistar rats |
Dosage: | 16 mg/kg |
Administration: | Intravenous infusion; 30 min before LPS intravenous injection |
Result: | Decreased pulmonary microvascular leakage in rats. |
AC-PHE-GLU-TRP-THR-PRO-GLY-TRP-TYR-GLN-L-AZETIDINE-2-CARBONYL-TYR-ALA-LEU-PRO-LEU-NH2 价格(试剂级)
更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
---|---|---|---|---|---|
2024-11-08 | HY-P1110 | AC-PHE-GLU-TRP-THR-PRO-GLY-TRP-TYR-GLN-L-AZETIDINE-2-CARBONYL-TYR-ALA-LEU-PRO-LEU-NH2 | 185413-30-3 | 1mg | 1200 |
2024-11-08 | HY-P1110 | AC-PHE-GLU-TRP-THR-PRO-GLY-TRP-TYR-GLN-L-AZETIDINE-2-CARBONYL-TYR-ALA-LEU-PRO-LEU-NH2 | 185413-30-3 | 5mg | 3500 |